GAMMA Investing LLC Acquires New Holdings in Bruker Co. (NASDAQ:BRKR)

GAMMA Investing LLC bought a new position in Bruker Co. (NASDAQ:BRKR) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 456 shares of the medical research company’s stock, valued at approximately $33,000.

Other large investors have also recently bought and sold shares of the company. Massachusetts Financial Services Co. MA raised its position in shares of Bruker by 8.2% in the third quarter. Massachusetts Financial Services Co. MA now owns 7,840,735 shares of the medical research company’s stock worth $488,478,000 after buying an additional 594,362 shares in the last quarter. RTW Investments LP raised its holdings in shares of Bruker by 14.3% in the 3rd quarter. RTW Investments LP now owns 3,381,703 shares of the medical research company’s stock valued at $210,680,000 after acquiring an additional 422,100 shares in the last quarter. Invesco Ltd. boosted its position in shares of Bruker by 3.0% during the 3rd quarter. Invesco Ltd. now owns 1,950,145 shares of the medical research company’s stock valued at $121,494,000 after acquiring an additional 56,869 shares during the last quarter. TD Asset Management Inc grew its holdings in shares of Bruker by 2.6% during the third quarter. TD Asset Management Inc now owns 1,102,095 shares of the medical research company’s stock worth $68,661,000 after purchasing an additional 28,031 shares in the last quarter. Finally, Ameriprise Financial Inc. increased its position in shares of Bruker by 95.2% in the third quarter. Ameriprise Financial Inc. now owns 928,418 shares of the medical research company’s stock worth $57,840,000 after purchasing an additional 452,780 shares during the last quarter. 79.52% of the stock is owned by institutional investors.

Bruker Trading Down 0.1 %

NASDAQ BRKR opened at $70.04 on Monday. The firm has a market cap of $10.18 billion, a PE ratio of 25.47, a price-to-earnings-growth ratio of 1.73 and a beta of 1.22. Bruker Co. has a 1-year low of $53.79 and a 1-year high of $94.86. The stock has a 50-day moving average of $87.38 and a 200-day moving average of $75.25. The company has a current ratio of 1.81, a quick ratio of 0.99 and a debt-to-equity ratio of 0.95.

Bruker (NASDAQ:BRKR) last released its quarterly earnings data on Thursday, May 2nd. The medical research company reported $0.53 earnings per share for the quarter, beating analysts’ consensus estimates of $0.46 by $0.07. Bruker had a return on equity of 27.31% and a net margin of 13.38%. The firm had revenue of $721.70 million during the quarter, compared to analyst estimates of $729.88 million. During the same quarter in the prior year, the firm posted $0.64 earnings per share. The business’s quarterly revenue was up 5.3% compared to the same quarter last year. As a group, sell-side analysts forecast that Bruker Co. will post 2.82 EPS for the current year.

Bruker Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, March 15th. Shareholders of record on Friday, March 1st were issued a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a yield of 0.29%. The ex-dividend date was Thursday, February 29th. Bruker’s dividend payout ratio (DPR) is presently 7.27%.

Wall Street Analysts Forecast Growth

BRKR has been the subject of several research analyst reports. The Goldman Sachs Group lifted their target price on shares of Bruker from $66.00 to $74.00 and gave the company a “sell” rating in a research report on Wednesday, April 10th. UBS Group upped their target price on shares of Bruker from $94.00 to $102.00 and gave the stock a “buy” rating in a research report on Friday, March 1st. Citigroup raised their price target on Bruker from $80.00 to $95.00 and gave the company a “buy” rating in a research report on Wednesday, February 14th. JPMorgan Chase & Co. upgraded Bruker from a “neutral” rating to an “overweight” rating and upped their price objective for the stock from $60.00 to $90.00 in a report on Wednesday, February 14th. Finally, Stifel Nicolaus raised their price objective on Bruker from $63.00 to $81.00 and gave the company a “hold” rating in a report on Wednesday, February 14th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, Bruker has an average rating of “Moderate Buy” and a consensus target price of $84.86.

Insider Buying and Selling at Bruker

In other news, Director Hermann Fritz Requardt sold 15,000 shares of the stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $90.06, for a total transaction of $1,350,900.00. Following the completion of the sale, the director now directly owns 23,147 shares in the company, valued at $2,084,618.82. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 28.30% of the company’s stock.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.